SenoMune-0257
Asset
Stimulates cytotoxic T cells to selectively eliminate senescent cells while sparing healthy cells.
- Stage
- Preclinical
- Modality
- Peptide
- Target
- Cellular senescence
- 1
- Indication
- 0
- Trials
- 1
- Developer
Indications
1Aging
Preclinical, longevity.technology, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Evidence for its targets1
- Competitors4
- Aging relevance1
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.